drug development Related News
The pharmaceutical industry responds to the Brexit White Paper
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (APBI) and BioIndustry Association’s (BIA) chief executive Steve Bates have issued a...
EMA: Ramp up efforts to ensure EU medicine supply post-Brexit
The European Medicines Agency (EMA) has warned that some companies need to take further action to safeguard the EU medicine supply once the UK...
Newly appointed ABPI president aims to transform patient care
The newly appointed president of the Association of the British Pharmaceutical Industry (ABPI), Erik Nordkamp, has set his sights on helping to transform patient...
Nobel Prize-winning technology has revealed herpes virus structure
Researchers at the Medical Research Council (MRC), UK, have successfully used the Nobel Prize-winning technology cryo-electron microscopy to reveal a detailed structure of the...
Welcome to the Kuopio Center for Gene and Cell Therapy
The Kuopio Center for Gene and Cell Therapy is home to the research and development of new innovative medicines.
The Kuopio Center for Gene and...
New therapy developed to treat lysosomal storage disease
Scientists at the University of Manchester, UK, have developed a new gene therapy that will hopefully be used to treat children with Sanfilippo, a...
An effective new treatment for cerebral malaria in mice found
Scientists from the universities of Manchester and Glasgow in the UK have found a potentially new way of treating cerebral malaria in a study...
AMPK activator O304 – a novel treatment for Type 2 diabetes and diabetic kidney...
The high and increasing unmet patient need in diabetic kidney disease demands new drugs. Betagenon AB has the answer.
Globally, approximately 40% of Type 2...
European Medicines Agency prepares pharmaceutical companies for Brexit
The European Medicines Agency (EMA) and the European Commission have updated their guidance which will help pharmaceutical companies prepare for the UK’s withdrawal from...
First of its kind AST-VAC2 vaccine gets tested to treat lung cancer
In a collaboration agreement between Cancer Research UK (CRUK) and Asterias, a first of its kind vaccine, AST-VAC2, has entered into a phase I...
Antibody therapy for migraine prevention set for marketing authorisation
The first monoclonal antibody therapy for migraine prevention, Aimovig, has been recommended for marketing authorisation by the European Medicines Agency's (EMA) Committee for Medicinal...
Could natural defence mechanisms be key to tackling antibiotic resistance?
A discovery of natural peptides that fight bacteria have been identified by the Technical University of Denmark, which could be vital in the battle...
Antifungal drug shows promise in the treatment of bowel cancer
An antifungal medication that’s commonly used for toenail infections could help eliminate dormant bowel cancer cells, new research suggests.
Research from the Cancer Research UK...
New Hepatitis C model developed that could improve treatment
A new mathematical model has been created by the University of Surrey, UK, which details how the Hepatitis C (HCV) infection develops and behaves,...
Trial launches to test new treatment combination for leukaemia patients
A clinical trial testing a new treatment combination for children and adults with leukaemia has been launched today through the Combinations Alliance.
The aim of...
A new approach to the treatment of prostate cancer
By understanding the production of specific human sex hormones, it can help develop new treatments for prostate cancer and polycystic ovary syndrome, a new...
Ebola vaccine being given to ‘high risk’ Democratic Republic of the Congo
With support of the WHO and partners, the Government of the Democratic Republic of Congo is preparing the Ebola vaccine for high risk populations...
European Commission approves single pill for HIV-1 treatment
The Janssen Pharmaceutical Companies of Johnson & Johnson have today announced that the European Commission has approved JULUCA® (dolutegravir/rilpivirine), a once daily single pill...
EMA recalls multiple sclerosis drug from hospitals and pharmacies
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that the multiple sclerosis drug Zinbryta has been recalled from hospitals and...
NICE recommends Biogen’s Avonex for multiple sclerosis
The National Institute for Heath and Care Excellence (NICE) has announced its recommendation of Biogen’s Avonex® (interferon beta-1a), which is used as an option...
